公开(公告)号：US20060040389A1

公开(公告)日：2006-02-23

申请号：US10920795

申请日：2004-08-17

Applicant: Charles Murry ,  Michael Laflamme

Inventor： Charles Murry ,  Michael Laflamme

IPC: C12N5/08 ,  G01N33/567

CPC classification number: G01N33/5073 ,  C12N5/0657 ,  G01N35/0098

Abstract: Viable differentiating cells from in vitro cultures of stem cells are selected for by partial dissociation to provide cell aggregates. Aggregates comprising cells of interest are selected for phenotypic features using methods that substantially maintain the cell to cell contacts in the aggregate.

Abstract translation: 通过部分解离选择来自干细胞的体外培养物的可行分化细胞以提供细胞聚集体。 使用将细胞基本上维持在聚集体中的细胞接触的方法，选择包含感兴趣的细胞的聚集体用于表型特征。

公开(公告)号：US09868937B2

公开(公告)日：2018-01-16

申请号：US14122226

申请日：2012-05-29

Applicant: Michael Regnier ,  Michael Laflamme ,  Charles Murry ,  F. Steven Korte ,  Scott Lundy ,  Stephen Denison Hauschka ,  Jeffrey S. Chamberlain ,  Guy Odom

Inventor： Michael Regnier ,  Michael Laflamme ,  Charles Murry ,  F. Steven Korte ,  Scott Lundy ,  Stephen Denison Hauschka ,  Jeffrey S. Chamberlain ,  Guy Odom

IPC: C12N5/077 ,  C12N9/02 ,  A01K67/027 ,  A61K48/00 ,  C07K14/47 ,  C12N15/85 ,  A61K9/00 ,  A61K35/34 ,  C12N7/00 ,  C12N15/86

CPC classification number: C12N5/0657 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K9/0019 ,  A61K35/34 ,  A61K48/005 ,  C07K14/4716 ,  C12N7/00 ,  C12N9/0093 ,  C12N15/8509 ,  C12N15/86 ,  C12N2750/14132 ,  C12N2750/14143 ,  C12N2799/022 ,  C12N2799/025 ,  C12Y117/04001 ,  C12Y117/04002

Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

公开(公告)号：US20070166288A1

公开(公告)日：2007-07-19

申请号：US11336502

申请日：2006-01-19

Applicant: Charles Murry ,  Michael Laflamme

Inventor： Charles Murry ,  Michael Laflamme

IPC: A61K35/12 ,  C12N5/08

CPC classification number: A61K38/30 ,  A61K31/4409 ,  A61K35/34 ,  A61K38/06 ,  A61K38/13 ,  A61K38/1761 ,  A61K38/55 ,  A61K45/06 ,  A61K2300/00

Abstract: The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.

Abstract translation: 移植期间细胞的存活率增强。 要移植的细胞在提供两个更多生存增强因子的制剂中施用。 任选地，在施用之前，在存在增强存活的因素的情况下培养细胞，并且可以在移植前热休克。